Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00006113 · University of Southern California · PHASE2 · terminated · last registry update 2014-05-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of efficacy” | – | Registry record, University of Southern California |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-04-13Results posted on the registry: Peking University People's Hospital, Interleukin-2 (NCT02084238)
- 2015-04-08Phase 3 first posted: Adienne SA, Begelomab + Conventional Second-line Treatment (NCT02411084)
- 2015-02-19Results posted on the registry: National Cancer Institute (NCI), Aldesleukin + Dinutuximab (NCT01041638)
- 2014-12-17Results posted on the registry: Wake Forest University Health Sciences, Tumor Infiltrating Lymphocytes (TIL) (NCT00863330)
- 2014-10-30Phase 3 first posted: The Netherlands Cancer Institute, Cyclophosphamide + Fludarabine (NCT02278887)
- 2014-07-04Results posted on the registry: Baylor College of Medicine, IL-2 (NCT00539695)
- 2014-06-02Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Administration of Lymphodepletion + High Dose IL-2 (NCT01005745)
- 2014-05-12Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), IL-2 (NCT00110812)
- 2013-09-04Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Cyclophosphamide + Doxorubicin (NCT00101101)
- 2013-07-02Results posted on the registry: The University of Texas Health Science Center at San Antonio, Denileukin Diftitox/SC Pegylated IFNα-2a (NCT01773889)
- 2013-06-26Results posted on the registry: Masonic Cancer Center, University of Minnesota, Natural Killer Cells + Fludarabine (NCT01106950)
- 2013-06-10Results posted on the registry: Dartmouth-Hitchcock Medical Center, Aldesleukin, + autologous tumor cell vaccine (NCT00085436)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision